These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 7760008)

  • 1. Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1.
    Hurley JM; Shimonkevitz R; Hanagan A; Enney K; Boen E; Malmstrom S; Kotzin BL; Matsumura M
    J Exp Med; 1995 Jun; 181(6):2229-35. PubMed ID: 7760008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis of the TCR binding domain of toxic shock syndrome toxin-1 predicts further diversity in MHC class II/superantigen/TCR ternary complexes.
    McCormick JK; Tripp TJ; Llera AS; Sundberg EJ; Dinges MM; Mariuzza RA; Schlievert PM
    J Immunol; 2003 Aug; 171(3):1385-92. PubMed ID: 12874229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
    von Bonin A; Ehrlich S; Malcherek G; Fleischer B
    Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules.
    Soos JM; Russell JK; Jarpe MA; Pontzer CH; Johnson HM
    Biochem Biophys Res Commun; 1993 Mar; 191(3):1211-7. PubMed ID: 8466498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding sites for bacterial and endogenous retroviral superantigens can be dissociated on major histocompatibility complex class II molecules.
    Thibodeau J; Labrecque N; Denis F; Huber BT; Sékaly RP
    J Exp Med; 1994 Mar; 179(3):1029-34. PubMed ID: 8113671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen.
    Panina-Bordignon P; Fu XT; Lanzavecchia A; Karr RW
    J Exp Med; 1992 Dec; 176(6):1779-84. PubMed ID: 1460432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality.
    Kum WW; Laupland KB; Chow AW
    Can J Microbiol; 2000 Feb; 46(2):171-9. PubMed ID: 10721486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enterotoxin residues determining T-cell receptor V beta binding specificity.
    Irwin MJ; Hudson KR; Fraser JD; Gascoigne NR
    Nature; 1992 Oct; 359(6398):841-3. PubMed ID: 1436060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The alpha 1 domain of the HLA-DR molecule is essential for high-affinity binding of the toxic shock syndrome toxin-1.
    Karp DR; Teletski CL; Scholl P; Geha R; Long EO
    Nature; 1990 Aug; 346(6283):474-6. PubMed ID: 2377209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification from a phage display library of peptides that bind to toxic shock syndrome toxin-1 and that inhibit its binding to major histocompatibility complex (MHC) class II molecules.
    Sato A; Ida N; Fukuyama M; Miwa K; Kazami J; Nakamura H
    Biochemistry; 1996 Aug; 35(32):10441-7. PubMed ID: 8756700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human scFvs That Counteract Bioactivities of Staphylococcus aureus TSST-1.
    Rukkawattanakul T; Sookrung N; Seesuay W; Onlamoon N; Diraphat P; Chaicumpa W; Indrawattana N
    Toxins (Basel); 2017 Feb; 9(2):. PubMed ID: 28218671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staphylococcal enterotoxin A and toxic shock syndrome toxin compete with CD4 for human major histocompatibility complex class II binding.
    Bavari S; Ulrich RG
    Infect Immun; 1995 Feb; 63(2):423-9. PubMed ID: 7822006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of HLA-DR1 beta chain residues critical for binding staphylococcal enterotoxins A and E.
    Karp DR; Long EO
    J Exp Med; 1992 Feb; 175(2):415-24. PubMed ID: 1370684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The crystal structure of staphylococcal enterotoxin H: implications for binding properties to MHC class II and TcR molecules.
    Hâkansson M; Petersson K; Nilsson H; Forsberg G; Björk P; Antonsson P; Svensson LA
    J Mol Biol; 2000 Sep; 302(3):527-37. PubMed ID: 10986116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1.
    Kim J; Urban RG; Strominger JL; Wiley DC
    Science; 1994 Dec; 266(5192):1870-4. PubMed ID: 7997880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
    Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
    Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequences in both class II major histocompatibility complex alpha and beta chains contribute to the binding of the superantigen toxic shock syndrome toxin 1.
    Braunstein NS; Weber DA; Wang XC; Long EO; Karp D
    J Exp Med; 1992 May; 175(5):1301-5. PubMed ID: 1569399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of toxic shock syndrome toxin-1 to murine major histocompatibility complex class II molecules.
    Scholl PR; Sekaly RP; Diez A; Glimcher LH; Geha RS
    Eur J Immunol; 1990 Sep; 20(9):1911-6. PubMed ID: 2209697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1.
    Acharya KR; Passalacqua EF; Jones EY; Harlos K; Stuart DI; Brehm RD; Tranter HS
    Nature; 1994 Jan; 367(6458):94-7. PubMed ID: 8107781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
    Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
    Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.